JHL Biotech and Affinita Biotech Agree to Partner
Complete the form below to unlock access to ALL audio articles.
JHL Biotech, Inc. has announced it has entered into a contract manufacturing master service agreement with Affinita Biotech. The agreement covers a development and manufacturing partnership for Affinita’s oncology monoclonal antibodies.
The agreement, extending to 2020, is estimated to be worth up to US$20 million in value. JHL will
provide cell line development, process development, and manufacturing expertise. The activities will
be carried out in JHL's Zhubei site in Taiwan as well as at JHL’s manufacturing facility in Wuhan,